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5  Background 
	
Ensuring	access	 to	 low-cost,	high	quality,	 self-test	pregnancy	 tests	has	been	 shown	 to	
increase	same-day	provision	of	family	planning,	and	aid	in	the	timely	provision	of	antenatal	care	
(5-8).	 However,	 in	many	 settings,	 pregnancy	 tests	 are	 not	 routinely	 available	 for	 clients,	 are	
marked	 up	 to	 unaffordable	 prices	 and/or	 are	 of	 questionable	 quality.	 In	 2015,	 FHI	 360	
partnered	with	Marie	Stopes	International	to	conduct	an	assessment	in	three	countries	(Kenya,	



































In	 2016,	 with	 support	 from	 the	 USAID-funded	 Envision	 FP	 project	 led	 by	 FHI	 360,	 this	
document	was	developed	to	address	some	of	these	gaps	in	knowledge	and	practice	by	outlining	




FIND’s	 initiatives	 towards	 the	 improvements	 of	 quality	 of	malaria	 rapid	 diagnostics	 (MRDTs),	












































































































































































































































































































































































8	Diagrams	have	been	adapted	from	Malaria rapid diagnostic test performance: Results of WHO product testing of malaria 
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 11.2.2 Reco mmended ana lyt ic al  sen si t iv i ty  (a lso  known  as detect ion  





























Details of any substances that have been tested and shown to cause interference with 
test performance: 1) analyte-independent interferences caused by agents such as 
caffeine, glucose, hemoglobin, albumin, bilirubin and 2) analyte-dependent 
interferences/cross-reactivity caused by disease states, such as rheumatoid arthritis 
and syphilis, should be stated. Commonly used medications, such as pain relievers, 
antibiotics and contraceptives, should not interfere with test performance and 
evidence should be provided to support claims (9,10, 24).  
 Recommended	%	Accuracy 11.2.5
This value should not exceed 99%.  Statements such as ‘100% accurate, virtually 100% 
accurate, nearly 100% accurate,’ must always be proven by detailed clinical evidence 
(performance evaluation) (9) 
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 Recommended Labeling Requirements for Secondary Packaging 11.6
































 Recommended Label ing  Requirements  for  Pr imary  Packag ing  11.7
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15     Annexes 
 Annex  S1:  Exp loratory  ana lys is  o f  pregnancy  tests  purchased 15.1
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 Annex S2: Quality approval of other Stringent Regulatory 15.2
Authorit ies (SRA) for consideration in the procurement of self-














































































	 Yes	 No	 NA	 Comments/problems	
List	of	Documents	to	be	Provided	by	Manufacturer	
1. ISO	13485	certification	 	 	 	 	
2. CE	Declaration	of	Conformity	(if	
applicable)		
	 	 	 	
3. FDA	510	Clearance	Status	(if	applicable)		 	 	 	 	
4. Product	Stability	Documentation		 	 	 	 	
5. Certificate	of	Analysis		 	 	 	 	








	 	 	 	
9. Compliant	with	a	different	standard	
(state	the	standard	under	comments)	
	 	 	 	




	 	 	 	
12. CE-marking	is	conformant		 	 	 	 	




	 	 	 	
Labeling/Marking	on	Secondary	Packaging	(Carton	and	Boxes)	
15. Commercial	name	of	the	test	included	 	 	 	 	
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16. Batch/lot	number	included		 	 	 	 	
17. Expiry	date/shelf-life	included		 	 	 	 	
18. Name	and	address	of	manufacturer	
included		
	 	 	 	
19. Contact	details	of	a	‘local	authorized	
person’	included	(if	applicable)		
	 	 	 	
20. CE-marking	is	conformant		 	 	 	 	
21. Identification	number	of	notified	body	is	
present		
	 	 	 	
22. Catalog	number	included	 	 	 	 	
23. Manufacturing	date	included	 	 	 	 	
24. Storage/handling	conditions	are	
included	
	 	 	 	
25. Clear	indication	of	in	vitro	diagnostic	
status	included	





	 	 	 	
27. Pregnancy	tests	are	in	individually	
sealed	pouches	and	are	intact	
	 	 	 	
28. Shelf-life	indicated	on	the	product	label	 	 	 	 	
29. The	product	has	not	exceeded	1/6th	of	
its	effective	shelf-life	
	 	 	 	
30. The	tests	are	stable	up	to	30	°C	 	 	 	 	
31. Recommend	storage	conditions	
indicated	on	the	product	label	











	 	 	 	




	 	 	 	
35. Desiccant	is	packaged	in	material	that	is	
permeable	to	air		
	 	 	 	
36. Desiccant	packaging	has	adequate	
labeling		
	 	 	 	
Ashini	Fernando	
PUBH	992:	Master’s	Paper	
62	|	P a g e 	
	




	 	 	 	
39. The	product	information	is	for	the	
correct	product	
	 	 	 	
40. Instructions	for	use	is	provided	 	 	 	 	
41. Declared	reading	time	is	provided	(time	
to	read	results)	




	 	 	 	
43. Materials	provided	and	materials	
required	but	not	provided	is	included		
	 	 	 	
44. Analytical	performance	information	is	
included	(sensitivity	and	specificity)	






	 	 	 	
47. Specificity	results	indicated	(reactivity	
with	FSH,	TSH,	LH)	
	 	 	 	
48. Where	not	obvious,	intended	use,	‘for	
pregnancy	testing’,	is	clearly	indicated		
	 	 	 	
49. Local	product	support	contact	details	
included		




	 	 	 	
51. %	Accuracy	is	<99%		 	 	 	 	
52. Interference	substances	indicated	 	 	 	 	
53. A	summary	of	the	test	is	included		 	 	 	 	
54. Principle	of	the	procedure	is	included	 	 	 	 	
55. Quality	control	measures	are	included	 	 	 	 	
56. Product	information	is	in	national	
language	
	 	 	 	
57. Disposal	instructions	included	 	 	 	 	
58. Limitations	of	the	procedure	are	
included:	
	 	 	 	




















	 	 	 	
	 	 	 	
	 	 	 	






















64	|	P a g e 	
	
 Annex  S4:  L i s t  o f  recommended procurement  gu idance  15.4
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 Annex  S7.  Use  of  pregnancy  tests  in  fami ly  p lanning  for  15.7



























 Annex S8: CE marking of conformity as specif ied in the 15.8
directive 98/79/EC of the European Parl iament and of the 


















 Annex S9: A Screenshot of FDA Premarket Notif ications (510(k) 15.9
clearance webpage that wil l  direct procurers to identify the 





































































































 Annex S11: Example of recommended label ing on primary 15.11
and secondary packaging (25,26) 
	
For	the	safe	and	effective	use	of	medical	devices,	ISO	15223-1:2012	has	identified	the	symbols	
used	below	for	use	in	labelling,	in	combination	with	applicable	ISO	standards.	This	information	
is	provided	as	a	source	of	information	for	interpreting	the	meanings	of	symbols	as	they	appear	
in	various	packaging,	as	well	as	enhanced	quality	practices	to	aspire	towards.	
	
	
 
